|
Mar 1
|
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
|
|
Feb 27
|
Q4 2024 Vir Biotechnology Inc Earnings Call
|
|
Feb 27
|
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Feb 26
|
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
|
|
Feb 26
|
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 19
|
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
|
|
Feb 12
|
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
|
|
Jan 10
|
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
|
|
Jan 9
|
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
|
|
Jan 9
|
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
|
|
Jan 8
|
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment
|
|
Jan 8
|
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
|
|
Jan 8
|
Vir Biotechnology price target lowered to $14 from $15 at BofA
|
|
Oct 3
|
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
|
|
Jul 18
|
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
|
|
Jun 18
|
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
|
|
May 29
|
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
|
May 29
|
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
|
|
May 21
|
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
|
|
May 8
|
Analysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
|